Recce's R327 found effective against E.coli during clinical trial
Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.
GYG
7.52%
$27.42
![](/images/icons/chart-icon.png)
GUZMAN Y GOMEZ LIMITED - Corporate Spotlight
Market Cap $2.779B
!
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.